Ageing installs the anti-fibrotic switch that spiny mice are born with
Constant itaconate in aged niche macrophages blocks TET2 and methylates the IRF4 site at the TGFB1 enhancer, so pro-resolution signalling stops driving scar formation. The gap between humans and the regenerating spiny mouse Acomys would then be a difference of age, not of species.
Omega Point 1.0
Stage of verification
- Hypothesis published2026-09-14
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Lens
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.

Epigenetic mark
IRF4 half-site CpG methylation at the TGFB1 enhancer
A DNA methylation mark at the IRF4 half-site within the TGFB1 enhancer
Where this hypothesis actsCD163+ niche macrophages from aged (65–75) and young (20–30) human donors
Hypotheses on this target 1
Silencing
Expression induction
Reprogramming
Direct measurement1

What is proposed
Direct measurement
Measure methylation and its association with TGF-β1 secretion after SPM stimulation
With whatInstrument or assay
HowBisulfite sequencing of FACS-sorted CD163+ macrophages from bone marrow aspirates, paired with ex vivo SPM stimulation and TGF-β1 ELISA
Possible result
Expected >60% methylation in aged donors and <10% in young donors, inversely correlated with TGF-β1 secretion
From the recordBisulfite sequencing of the IRF4 half-site CpG at the TGFB1 enhancer in FACS-sorted CD163+ niche macrophages

Immune cell
Macrophages
Immune cells that can undergo M2 polarization and secrete TGF-β1
Where this hypothesis actsHuman niche macrophages from aged and young donors, tested ex vivo
Hypotheses on this target 2
Activation
Clearance restoration
Reprogramming2
Adoptive transfer
Elimination
Immunosuppression
Population balance

What is proposed
Reprogramming
Induce M2 polarization with SPM stimulation
With whatSmall molecule
HowEx vivo SPM polarization assays with TGF-β1 secretion measured by ELISA
Possible result
Expected absence of increased TGF-β1 secretion in aged macrophages despite SPM-driven M2 polarization
From the recordSPM-driven M2 polarization in aged human niche macrophages therefore does NOT increase TGF-β1
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Restoring the surroundings that support stem cells may require separating the relief of inflammation from the signals that promote scarring. The unexpected move is that an age-related metabolic disturbance could itself install that separation in older human immune cells. This is a proposal generated by the pipeline, not a measured result.
- Ageing is proposed to sustain production of itaconate in niche macrophages.
- Persistent itaconate is proposed to inhibit TET2, an enzyme involved in removing methyl marks from genetic material.
- Reduced TET2 activity is proposed to increase methylation, the addition of chemical methyl marks, at a particular binding site in the TGFB1 enhancer, a region controlling the gene for transforming growth factor beta 1.
- The added marks are proposed to switch that site from permitting joint binding by two gene-regulating proteins to blocking their joint action.
- Inflammation-resolving stimulation would then produce the repair-associated cell state without the accompanying increase in transforming growth factor beta 1 secretion.
- The same persistent itaconate is also proposed to impair efferocytosis, the clearance of dead cells, while blocking this route to the scarring signal.
A shared light switch normally turns on two lamps, but a disconnected wire lets one lamp light while the other stays dark. The proposal is that ageing creates that disconnection.
Where the picture breaks: Gene control is not a fixed electrical circuit: chemical marking can change, other signals can affect the same gene, and blocking one route does not establish that scarring stops.
- Master questionstep 01 of 04
Rejuvenating the stem cell niche—the local cells, materials and signals that support stem cells—is the overarching aim.
Rests on: The goal treats the condition of those surroundings as a target for rejuvenation.
AssumptionThe goal assumes that restoring the supporting environment can contribute to rejuvenation; it supplies no tissue, intervention or measure of success.
- Goal pillarstep 02 of 04
Weakening a cycle in which tissue mechanics and inflammation reinforce each other is selected as a route toward rejuvenating that environment.
Rests on: This requires a connection between the condition of the stem cell environment and a self-reinforcing interaction between physical forces and inflammation.
LeapThe master question does not establish that such a cycle drives deterioration or that weakening it restores stem cell support.
- Gap questionstep 03 of 04
Specialized pro-resolving mediators, signals that help inflammation end, may increase or decrease secretion of transforming growth factor beta 1, a signal associated with scarring, when human niche macrophages enter an M2 state, a repair-associated activation pattern. The question takes as its premise that humans lack a chemical marking arrangement in spiny mice that separates inflammation resolution from scarring.
Rests on: Separating inflammation relief from scarring would address the selected interaction between inflammation and tissue mechanics, provided the stated species difference exists.
AssumptionThe spiny-mouse marking arrangement and its absence in humans are taken as given. Neither the preceding stage nor the supplied screened sources establishes that comparison.
- Hypothesisstep 04 of 04
Older human macrophages are proposed to acquire the separation attributed to spiny mice. Persistent itaconate, a metabolic product, would inhibit an enzyme involved in removing chemical marks from genetic material, allowing marks to accumulate at a gene-control site and preventing inflammation-resolving stimulation from increasing the scarring signal.
Rests on: The preceding question supplies the idea that chemical marking can separate inflammation resolution from scarring. The endpoint adds persistent itaconate and age-dependent marking as the proposed human route to that separation.
LeapThe missing bridge is evidence or an established premise connecting ageing, persistent itaconate and the particular human gene-control site. The internal reference cited for aged-cell itaconate is not supplied as evidence, and no screened source establishes this connection. The gap concerns the borrowed basis, not the proposal's being untested.
What is carried, and what is not. One screened source directly addresses the itaconate-to-scarring-signal connection: Redox Biology (2023), S4, reports increased expression of the gene for transforming growth factor beta 1 with late-phase itaconate production in human macrophages derived from blood cells, a direction that challenges the proposal but does not establish secretion or effects in aged niche cells. None of the supplied screened sources establishes the proposed age-dependent marking switch or the sequence end to end.S4
Where the reasoning is carried by something unstated · 4
- Master question. The goal assumes that restoring the supporting environment can contribute to rejuvenation; it supplies no tissue, intervention or measure of success.
- Goal pillar. The master question does not establish that such a cycle drives deterioration or that weakening it restores stem cell support. Establish the missing link before relying on this step.
- Gap question. The spiny-mouse marking arrangement and its absence in humans are taken as given. Neither the preceding stage nor the supplied screened sources establishes that comparison.
- Hypothesis. The missing bridge is evidence or an established premise connecting ageing, persistent itaconate and the particular human gene-control site. The internal reference cited for aged-cell itaconate is not supplied as evidence, and no screened source establishes this connection. The gap concerns the borrowed basis, not the proposal's being untested. Establish the missing link before relying on this step.
How a result here could mislead · 3
- Greater marking alongside lower secretion in older donors could be read as proof that itaconate caused the marking and that the marking caused reduced secretion. The proposed comparison measures an association and does not separate that route from the rivals involving metabolic state or altered reception of resolving signals. What closes it: A causal test would need to change the proposed itaconate–TET2 route, verify the resulting change at the specified site, and measure secretion alongside the cell response to resolving stimulation. The supplied test does not specify these interventions.
- A difference in secretion after cells are removed from the body could be attributed to age-dependent marking even if the stiffness of the culture surface produces the difference through another route. What closes it: Culture-surface stiffness must be controlled and reported, with the age comparison repeated under the soft conditions proposed by the stiffness rival. The supplied test does not specify substrate conditions.
- Lower measured secretion could be taken to mean less scarring in the niche, although the barrier rival predicts that access to neighbouring cells and activation of the signal determine its effect. What closes it: The study must distinguish the amount secreted from the amount biologically active and establish whether it reaches and affects neighbouring scar-producing cells. Secretion measurements alone do not settle that rival.
What would make this wrong. The stated prediction would fail if macrophages from donors aged 65–75 did not show greater than 60% marking at the specified site while those from donors aged 20–30 showed less than 10%, or if greater marking did not accompany lower secretion after resolving stimulation. More directly, verified removal of the proposed marking without restoration of the secretion response, despite preserved responsiveness to stimulation, would break the claimed marking-to-output link. The supplied material contains no results from these tests.
What it would change. If this mechanism held, an age-related disturbance could impair dead-cell clearance while also blocking one route from inflammation resolution to scarring. Work toward stem cell niche rejuvenation would need to account for both effects when changing that disturbance. Even a successful donor-cell test would not establish reduced scarring, restored stem cell function or rejuvenation in a living human niche.
Sources read · 3
Thrombospondin-1-mediated macrophage efferocytosis dysfunction exacerbates intestinal pathology in Hirschsprung's disease. · International immunopharmacology · 2026
“HSCR macrophages exhibited proinflammatory hyperactivation and impaired pro-resolving polarization with reduction of CD206+ proportion and downregulation of TGFB1.”
Does not settle: This abstract does not assess ageing, young versus aged human macrophages, niche macrophages, spiny mice, SPM treatment, itaconate/IRG1, TET2, IRF4/STAT6 co-binding, TGFB1-enhancer methylation, or an age-dependent epigenetic mechanism.
Efferocytosis by Macrophages Attenuates Inflammatory Responses Following Ultraviolet B-Induced Apoptosis in Corneal Stromal Cells. · Investigative ophthalmology & visual science · 2025
“Microenvironmental M1 macrophages exhibited reduced IL-1β, increased transforming growth factor beta 1, and downregulation of CD14, CD68, CD80, and CD11c.”
Does not settle: It does not examine aged versus young human niche macrophages, SPM-driven M2 polarization, IRG1-itaconate, TET2, DNA methylation, IRF4/STAT6 binding, the TGFB1 enhancer, Acomys, or an age-dependent epigenetic switch.
Itaconate promotes a wound resolving phenotype in pro-inflammatory macrophages. · Redox biology · 2023
“In this study, we show that the late-phase production of itaconate contributes to a pro-resolution phenotype in hMDMs, because it inhibits collagen uptake and promotes expression of TGFB1 and reduces MMP8 .”
Does not settle: This source does not establish effects in aged versus young human niche macrophages, SPM-driven polarization, TET2 activity, methylation of an IRF4 half-site at a TGFB1 enhancer, IRF4/STAT6 co-binding, efferocytosis, or an Acomys-like state.
The gap this hypothesis explains
Two established results predict opposite outcomes, and both cannot be right.
Do resolution signals make human repair macrophages release more of the scarring protein, or less?
Original wording · exactly as the pipeline generated it
Does SPM-driven M2 polarization in human niche macrophages increase or decrease TGF-β1 secretion, given that the Acomys IRF4-half-site CpG methylation decoupling pro-resolution from fibrosis is absent in humans?
What this question is asking
The question asks whether signals that help inflammation end also increase or decrease a protein that can promote scarring. Specifically, it asks whether specialized pro-resolving mediators (SPMs) push macrophages in the human stem cell niche toward an M2 repair-associated state and change their release of transforming growth factor beta 1 (TGF-β1), compared with otherwise comparable cells without that treatment. Its premise is that African spiny mice have a chemical mark at an interferon regulatory factor 4 (IRF4) half-site that separates inflammation resolution from scarring, and that humans lack this arrangement; the supplied sources do not establish that premise. The desired outcome is clearance of debris associated with senescent cells without activating scar-producing fibroblasts.
- Macrophage
- An immune cell that takes up cells and debris and releases signals that affect surrounding tissue. Its cleanup and signaling activities are the two functions being compared here.
- Inflammation resolution and specialized pro-resolving mediators (SPMs)
- Resolution is the process through which inflammation subsides. Specialized pro-resolving mediators are a class of signaling molecules associated with that process; the question asks whether their effects on cleanup also change a scar-promoting signal.
- M1, M2, polarization, and differentiation
- M1 and M2 are conventional labels for broadly inflammation-associated and repair-associated macrophage states. Polarization and differentiation describe shifts in cell characteristics; these labels summarize varied states rather than two fixed types, and M2 does not itself mean scar-free repair.
- Stem cell niche
- The local cells, signals, and physical surroundings that support stem cells, which can produce replacement cells. The question concerns macrophages in that environment, but the supplied input does not identify a particular human tissue niche.
- Transforming growth factor beta 1 (TGF-β1) and TGFB1
- TGF-β1 is a signaling protein described here in both inflammation-reducing and scar-promoting roles. TGFB1 names the gene encoding it; a change in gene expression does not by itself establish a change in protein release.
- Gene expression and protein secretion
- Gene expression is the use of genetic instructions to produce a cell's products. Secretion is release of a substance from the cell; the question asks about secretion, while S2 and S4 report expression of the gene encoding the protein.
- Fibroblast, fibroblast activation, fibrosis, and collagen
- Fibroblasts are cells that produce material supporting tissue, including the structural protein collagen. Activation can increase this activity, while fibrosis means excessive buildup of scar-like material; collagen uptake is removal into cells, not a direct measurement of scar formation.
- Senescent cells and aged red blood cells
- In the proposed niche problem, senescent cells are cells in a lasting state of no longer dividing. S7 concerns aged red blood cells, which carry oxygen; the supplied material does not establish that clearing them represents clearance of the senescent cells intended by the gap.
- Efferocytosis
- The process by which cells such as macrophages take up and clear dying cells. The sources use it for cleanup outcomes, which must be distinguished from measurements of released signaling proteins.
- Acomys
- The genus of African spiny mice named in the question. The proposed mechanism in these animals and its claimed absence in humans are premises under audit, not findings established by the supplied sources.
- Interferon regulatory factor 4 (IRF4) and half-site
- IRF4 is a protein that regulates gene activity by participating in binding to genetic material. A half-site is part of a larger binding pattern; the input proposes a mechanism involving such a site but supplies no establishing evidence.
- CpG methylation
- CpG denotes a cytosine followed by a guanine in deoxyribonucleic acid, the material carrying genetic instructions; the letter p represents the connecting phosphate. Methylation is addition of a chemical mark at such a site, proposed here to alter the relationship between inflammation resolution and scarring.
- Co-binding
- Binding involving more than one participant at a site or target. The gap description uses this term for IRF4 and TGF-β1 without specifying the participants' roles or binding target, so its precise meaning is not established here.
- Human monocyte-derived macrophages
- Macrophages developed from human monocytes, a type of blood immune cell. Findings in these cells do not by themselves establish the same response in macrophages within a stem cell niche.
- Corneal fibroblasts, ultraviolet B, and physical separation
- Corneal fibroblasts are support-producing cells from the eye's clear front surface. S2 uses ultraviolet B light to injure these cells and a compartment-separated laboratory setup involving macrophages; this is a different setting from the human niche specified in the question.
- Itaconate
- A molecule produced through cellular chemical processing. S4 links its late production to resolution-associated macrophage changes, but does not test the specialized pro-resolving mediator intervention asked about.
- Matrix metalloproteinase 8
- An enzyme involved in breaking down material surrounding cells. S4 reports its reduction alongside other changes, without establishing the requested TGF-β1 secretion outcome.
- 17R-resolvin D2
- The particular resolution-promoting signaling molecule studied in S7. Its reported effects on macrophage state and cell clearance provide nearby evidence, but not the requested measurement of TGF-β1 release.
- Glutamine metabolism
- The chemical processing of glutamine, a molecule cells use as a nutrient and building material. S5 connects that processing to M2 polarization without establishing the secretion response in the question.
Acomys IRF4-half-site CpG methylation decouples pro-resolution from fibrosis, and this decoupling mechanism is absent in humans.
The assumption concerns African spiny mice, a proposed short genetic binding site for a protein that regulates gene activity, and a chemical mark at that site. It claims that the mark lets inflammation subside without triggering scarring in these mice, while humans lack that separation. If established, this would supply a species-specific reason to question whether repair signals have the same scarring consequences in humans.
The supplied search results do not return work establishing either the proposed mouse mechanism or its absence in humans. S2 and S4 report changes in gene expression in other settings, S7 reports repair-associated and clearance effects of a resolution signal, and S5 and S9 concern other aspects of macrophage activity. None establishes the asserted species difference; this bounded set of sources does not show that the premise is false.S2S4S5S7S9
The same question asked without the part nothing read establishes:
- Does treatment with specialized pro-resolving mediators increase or decrease TGF-β1 release as macrophages in the human stem cell niche adopt an M2 repair-associated state?
- In macrophages in the human stem cell niche, does treatment with specialized pro-resolving mediators support debris clearance without increasing TGF-β1 release or fibroblast activation?
- TGF-β1 release increases Under the question's proposed mechanism, a treatment that promotes debris clearance would also increase a signal capable of activating fibroblasts. Clearance and scar-promoting activity could therefore rise together, so the repair-associated cell state would not by itself establish the desired separation.
- TGF-β1 release decreases If debris clearance also improved, the treatment would combine greater removal of unwanted material with less release of this scar-promoting signal. That would fit the requested separation at the level of these two measurements, but would not by itself establish reduced tissue scarring.
- No consistent direction If release remained unchanged or differed across conditions, the M2 label would not identify a consistent change in this signal. Any improvement in clearance would then leave the proposed effect on fibroblast activation unresolved.
The proposed chain starts with a signal changing the activity of tissue-cleaning immune cells. Those cells would need to remove debris while avoiding release of enough scar-promoting signals to activate fibroblasts. If the same treatment increased TGF-β1 release, interpreting a repair-associated cell state as evidence of scar-free repair could be mistaken. If it decreased release, assuming that repair-associated activity necessarily increases this scarring signal could also be mistaken. Neither direction alone would establish restoration of the environment that supports stem cells.
Two S-nodes predict opposite TGF-β1 outcomes from the same SPM intervention in human macrophages.
Macrophage polarization state that clears senescent debris without TGF-β1-driven fibroblast activation.
No human niche macrophage data on IRF4-TGF-β1 co-binding status during SPM-driven polarization; intervention direction is indeterminate.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Human niche macrophages possess a chromatin-state-dependent IRF4/STAT6 co-binding switch at the TGFB1 enhancer that is NOT constitutively locked but is dynamically regulated by the itaconate-TET2 axis: constitutive IRG1-itaconate in aged macrophages hypermethylates the IRF4 half-site CpG at the TGFB1 enhancer via TET2 inhibition, CREATING an Acomys-like decoupling state in aged but not young human macrophages. SPM-driven M2 polarization in aged human niche macrophages therefore does NOT increase TGF-β1 because the very metabolic pathology (chronic itaconate) that impairs their efferocytosis simultaneously methylates the IRF4-TGFB1 co-binding site. The apparent species difference is actually an age-dependent epigenetic state difference.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
Bisulfite sequencing of the IRF4 half-site CpG at the TGFB1 enhancer in FACS-sorted CD163+ niche macrophages will show >60%methylation in aged (65-75) human donors but <10%in young (20-30) donors, and this methylation will correlate inversely with TGF-β1 secretion upon SPM stimulation in ex vivo polarization assays.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies age-group methylation thresholds and an inverse relationship with stimulated TGF-β1 secretion. No rival prediction is supplied. A paper already fetched for this hypothesis bears on it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Bisulfite sequencing of sorted macrophages from bone marrow aspirates is routine; ex vivo SPM polarization + TGF-β1 ELISA is standard.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
Bisulfite sequencing of the IRF4 half-site CpG at the TGFB1 enhancer in FACS-sorted CD163+ niche macrophages will show >60% methylation in aged (65-75) human donors but <10% in young (20-30) donors, and this methylation will correlate inversely with TGF-β1 secretion upon SPM stimulation in ex vivo polarization assays.
- What would separate them
The fibrosis signal is stopped by the hyaluronan mesh, not by the macrophage predicts: In human niche explant co-cultures, adding exogenous ultra-HMW-HA (>6 MDa) to the macrophage-fibroblast interface will block TGF-β1-driven αSMA expression in fibroblasts even when macrophages are maximally M2-polarized with high TGF-β1 secretion, while low-MW HA (<500 kDa) will permit fibroblast activation at the same TGF-β1 concentration.
- Rival 02 of 04What would separate them
The link between resolving inflammation and fibrosis is an artefact of culture plastic predicts: Human monocyte-derived macrophages polarized with resolvin D1 on 2 kPa polyacrylamide gels will show <2-fold TGF-β1 increase vs. unpolarized controls, while the same cells on tissue culture plastic show >5-fold increase. YAP nuclear/cytoplasmic ratio will correlate with TGF-β1 output (r>0.7) across substrate stiffnesses.
- What would separate them
NAD+ decides whether a healing macrophage also turns fibrotic predicts: Pre-treatment of aged human macrophages with NMN (1mM, 48h) before SPM-driven M2 polarization will reduce TGF-β1 secretion by >50% compared to vehicle, and this effect will be abolished by SIRT6 inhibitor OSS_128167. ChIP-qPCR will show restored H3K9 deacetylation at the TGFB1 promoter in NMN-treated aged macrophages.
- What would separate them
Resolvins may drive fibrosis in aged cells rather than resolve it predicts: In aged human macrophages with documented low FPR2 surface density, resolvin D1 treatment will increase TGF-β1 secretion above untreated controls (not just fail to decrease it), and this increase will be blocked by β-arrestin-2 siRNA but not by pertussis toxin (Gαi inhibitor), confirming β-arrestin-biased signaling as the driver.
Why this is not the mainstream account
The engine is asked to say what its hypothesis would overturn and what would surprise a specialist. This is its answer.
documents constitutive IRG1-itaconate → TET2 inhibition in aged macrophages; TET2 controls CpG methylation at exactly the loci where the Acomys decoupling occurs.
Macrophage polarization biology — Chapter on M2 polarization and fibrosis coupling. Would rewrite the assumption that IRF4-TGFB1 co-binding is species-fixed.
Finding that aged human macrophages are MORE decoupled from fibrosis than young ones during SPM treatment would invert the entire therapeutic logic — young patients would need the decoupling intervention, not old ones.
No review or perspective argues that aged human macrophages acquire Acomys-like IRF4-TGFB1 decoupling via itaconate-TET2 methylation.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
2 quantitative figures appear below and the hypothesis cites no study for any of them. They are the engine's own, and the marks in the text say which.
What it would take to refute it. 1 paper(s) already retrieved for this hypothesis carry its prediction’s terms. Reading them comes before running anything. Already retrieved: Abstract Book for the 27th Congress of the European Hematology Association.
3 papers retrieved around this hypothesis
- Special Issue: EACR 2026 Congress: Innovative Cancer Science, 8-11 June 2026.PMID 42633749 · full_text · 1,706 characters stored
- Abstract Book for the 27th Congress of the European Hematology Associationeuropepmc:PMC:PMC9429973 · full_text · 8,794,916 characters stored
- Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020europepmc:PMC:PMC8901205 · full_text · 1,347 characters stored
0 citation handles extracted; 1 Europe PMC search run; 3 records examined; 3 sources stored for enrichment, 3 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.